Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure.
Van Vaerenbergh K, De Geest S, Derdelinckx I, Bobbaers H, Carbonez A, Deschamps A, De Graeve V, De Saar V, Ceunen H, De Smet K, Maes B, Peetermans W, Schrooten Y, Desmyter J, De Clercq E, Van Ranst M, Van Wijngaerden E, Vandamme AM. Van Vaerenbergh K, et al. Among authors: van wijngaerden e, van ranst m. Antivir Chem Chemother. 2002 Jul;13(4):231-40. doi: 10.1177/095632020201300404. Antivir Chem Chemother. 2002. PMID: 12495211 Free article.
Performance of the VERSANT HIV-1 resistance assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes.
Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Schouwer K, De Wit S, Fransen K, García Ribas S, Moutschen M, Vaira D, Zissis G, Van Ranst M, Van Wijngaerden E, Vandamme AM. Derdelinckx I, et al. Among authors: van laethem k, van wijngaerden e, van ranst m. FEMS Immunol Med Microbiol. 2003 Nov 28;39(2):119-24. doi: 10.1016/S0928-8244(03)00240-2. FEMS Immunol Med Microbiol. 2003. PMID: 14625094 Free article.
Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001.
Snoeck J, Van Laethem K, Hermans P, Van Wijngaerden E, Derdelinckx I, Schrooten Y, van de Vijver DA, De Wit S, Clumeck N, Vandamme AM. Snoeck J, et al. Among authors: van laethem k, van wijngaerden e, van de vijver da. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):279-85. doi: 10.1097/00126334-200403010-00009. J Acquir Immune Defic Syndr. 2004. PMID: 15076243
Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response.
Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Wit S, Florence E, Fransen K, Ribas SG, Marissens D, Moutschen M, Vaira D, Zissis G, Van Ranst M, Van Wijngaerden E, Vandamme AM. Derdelinckx I, et al. Among authors: van laethem k, van wijngaerden e, van ranst m. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1664-6. doi: 10.1097/00126334-200412150-00022. J Acquir Immune Defic Syndr. 2004. PMID: 15577426 Free article. Clinical Trial. No abstract available.
Prevalence and correlates of nonadherence to antiretroviral therapy in a population of HIV patients using Medication Event Monitoring System.
Deschamps AE, Graeve VD, van Wijngaerden E, De Saar V, Vandamme AM, van Vaerenbergh K, Ceunen H, Bobbaers H, Peetermans WE, de Vleeschouwer PJ, de Geest S. Deschamps AE, et al. Among authors: van vaerenbergh k, van wijngaerden e. AIDS Patient Care STDS. 2004 Nov;18(11):644-57. doi: 10.1089/apc.2004.18.644. AIDS Patient Care STDS. 2004. PMID: 15633262
Fatal brain necrosis in primary HIV infection.
Meersseman W, Van Laethem K, Lagrou K, Wilms G, Sciot R, Van Ranst M, Vandamme A, Van Wijngaerden E. Meersseman W, et al. Among authors: van laethem k, van wijngaerden e, van ranst m. Lancet. 2005 Sep 3-9;366(9488):866. doi: 10.1016/S0140-6736(05)67220-0. Lancet. 2005. PMID: 16139663 No abstract available.
159 results